CoronaVac

Also known as Sinovac COVID-19 vaccine, Sinovac vaccine, Chinese vaccine, Chinese coronavirus vaccine, PiCoVacc

Key facts

Drug.legal_BR: Emergency use
Drug.type: vaccine
Drug.image: CoronaVac.jpg
Drug.caption: An empty vial of the CoronaVac vaccine
Drug.target: SARS-CoV-2
Drug.vaccine_type: inactivated
Drug.tradename: CoronaVac
Drug.routes_of_administration: Intramuscular
Drug.ATC_prefix: J07
Drug.ATC_suffix: BN03
Drug.legal_status: Full list of CoronaVac authorizations
Drug.CAS_number: 2480309-93-9
Drug.DrugBank: DB15806
Drug.UNII: M1QXB372B8
Drug.synonyms: PiCoVacc

via Wikipedia infobox

Wikidata facts

Image: SINOVAC COVID-19 vaccine.jpg

Show 1 more fact

Commons category: CoronaVac

Sources (3)

via Wikidata · CC0

~25 min read

Article

32 sections

Contents

Medical uses
Effectiveness
Variants
In the elderly
Specific populations
Manufacturing
History
Clinical trials
Phase I–II
Phase III
Children and adolescents trials
Results of Phase III trials
Variability in results
Post phase III
Variants
Authorizations
Society and culture
Economics
Asia
Africa
Europe
South America
North America
Oceania
Controversies
China state media propaganda
Politicization
Delays in releasing results
Disinformation and influence operations
References
Further reading
External links

CoronaVac, also known as the Sinovac COVID-19 vaccine, was a whole inactivated virus SARS-CoV-2 vaccine developed by Sinovac and extensively deployed globally to control the COVID-19 pandemic. Its use was highest in low- and middle-income countries. In January 2024, Sinovac confirmed that production of CoronaVac had been discontinued.

Clinical trials have demonstrated that a standard two-dose regimen provides moderate efficacy against symptomatic COVID-19, ranging from about 50% to 83% depending on population and circulating viral variants, with more robust protection observed against severe disease, hospitalization, and death. Although most adverse reactions are mild and serious vaccine-related events are rare, the vaccine’s immune protection against symptomatic infection wanes over time, especially in the context of emerging variants such as Omicron, leading to recommendations for booster doses to sustain immunity and reduce severe outcomes. Overall, CoronaVac’s safety and efficacy profile in preventing severe COVID-19 have contributed to its use in vaccination programs, particularly in regions with limited access to mRNA vaccines.